Laurus Labs' Q3 FY 2025-26 Quarterly Results
- 24 Jan 2026
Result Summary
- Laurus Labs Ltd reported a 6.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 25.2%.
- Its expenses for the quarter were up by 3.3% QoQ and 12.7% YoY.
- The net profit increased 29.5% QoQ and increased 171.0% YoY.
- The earnings per share (EPS) of Laurus Labs Ltd stood at 4.65 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 1784.05 | 1680.43 | 1424.47 | 6.2% | 25.2% |
Total Expenses | 1457.49 | 1410.70 | 1293.79 | 3.3% | 12.7% |
Profit Before Tax | 326.56 | 269.73 | 130.68 | 21.1% | 149.9% |
Tax | 73.45 | 75.98 | 40.07 | -3.3% | 83.3% |
Profit After Tax | 251.88 | 194.49 | 92.94 | 29.5% | 171.0% |
Earnings Per Share | 4.65 | 3.61 | 1.71 | 28.8% | 171.9% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Laurus Labs Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the development, manufacture, and sale of generic active pharmaceutical ingredients (APIs). The company's portfolio spans across various therapeutic segments, including antiretrovirals, oncology, cardiovascular, and anti-diabetics. Laurus Labs has also ventured into formulation manufacturing and biotechnology, expanding its operational scope. As of the latest updates, the company has been focused on enhancing its manufacturing capabilities and expanding its global footprint to cater to a larger market. The company is known for its robust research and development efforts, aimed at introducing cost-effective and high-quality pharmaceutical products. Further specific company developments or strategic initiatives within the recent period are not available in the provided data.
Revenue
In Q3FY26, Laurus Labs Ltd reported a total income of ₹1784.05 crores, marking a significant increase compared to ₹1680.43 crores in Q2FY26 and ₹1424.47 crores in Q3FY25. This represents a quarter-over-quarter (QoQ) growth of 6.2% and a year-over-year (YoY) increase of 25.2%. The growth in total income suggests an expansion in sales or other income streams during the analyzed period. The financial data highlights the company's ability to enhance its revenue base over both short-term and long-term periods, reflecting a consistent upward trend in overall financial performance.
Profitability
The profitability metrics for Laurus Labs Ltd indicate a strong performance in Q3FY26. The profit before tax (PBT) was reported at ₹326.56 crores, an increase from ₹269.73 crores in Q2FY26 and ₹130.68 crores in Q3FY25. This translates to a QoQ growth of 21.1% and a substantial YoY increase of 149.9%. The profit after tax (PAT) also showed improvement, reaching ₹251.88 crores in Q3FY26, compared to ₹194.49 crores in Q2FY26 and ₹92.94 crores in Q3FY25, which marks a QoQ growth of 29.5% and a YoY growth of 171.0%. These metrics underscore the company's enhanced profitability over the reported periods. The earnings per share (EPS) followed a similar trajectory, rising to ₹4.65 in Q3FY26 from ₹3.61 in Q2FY26 and ₹1.71 in Q3FY25, reflecting a QoQ increase of 28.8% and a YoY increase of 171.9%.
Operating Metrics
Laurus Labs Ltd's operating metrics demonstrate a controlled increase in total expenses, recorded at ₹1457.49 crores in Q3FY26, up from ₹1410.70 crores in Q2FY26 and ₹1293.79 crores in Q3FY25. The expenses grew by 3.3% QoQ and 12.7% YoY, showing a relatively moderate increase compared to the growth in revenue. The tax paid decreased slightly from ₹75.98 crores in Q2FY26 to ₹73.45 crores in Q3FY26, while it increased from ₹40.07 crores in Q3FY25, indicating a YoY growth of 83.3% and a QoQ decline of 3.3%. The data suggests that the company has managed its operational costs effectively, contributing to its overall financial health during the quarter.